Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 51-55

  Kong, Qing You ^a   Liu, Jia ^a   Chen, Xiao Yan ^a   Wang, Xiao Wei ^a   Sun, Yuan ^a   Li, Hong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; CD44; Gene expression; RHAMM

Indexed keywords

HERMES ANTIGEN; HYALURONAN MEDIATED MOTILITY RECEPTOR; HYALURONAN-MEDIATED MOTILITY RECEPTOR; HYALURONIC ACID; SCLEROPROTEIN;

ADENOCARCINOMA; ALTERNATIVE RNA SPLICING; ARTICLE; BLADDER; BLADDER TUMOR; CANCER INVASION; CELL TRANSFORMATION; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; FROZEN SECTION; GENETICS; HUMAN; METABOLISM; MUCOSA; PATHOLOGY; PRECANCER; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; WESTERN BLOTTING;

ADENOCARCINOMA; ALTERNATIVE SPLICING; ANTIGENS, CD44; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; EXTRACELLULAR MATRIX PROTEINS; FROZEN SECTIONS; HUMANS; HYALURONIC ACID; IMMUNOENZYME TECHNIQUES; MUCOUS MEMBRANE; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0042810431     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.51     Document Type: Article

References (33)

1. Droller MJ: Markers for recurrence of superficial bladder cancer: what is valid? J Urol 164: 1840-1841, 2000.
2. Holmang S: Follow-up of patients with non-invasive and superficially invasive bladder cancer. Semin Urol Oncol 18: 273-279, 2000.
3. Segal AJ, Amis ES Jr, Bigongiari LR, Bluth EI, Bush WH Jr, Choyke PL, Fritzsche PJ, Holder LE, Newhouse JH, Sandler CM, Resnick MI and Rutsky EA: Follow-up imaging of bladder carcinoma. American College of Radiology. ACR Appropriateness Criteria. Radiology 215 (Suppl): 765-772, 2000.
4. Zieger K, Wolf H, Olsen PR and Hojgaard K: Long-term follow-up of non-invasive bladder tumors (stage Ta): recurrence and progression. Br J Urol Int 85: 824-828, 2000. (Pubitemid 30242785)
5. Van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH and Zwarthoff EC: Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 12: 2973-2980, 2000. (Pubitemid 32000770)
6. Hartmann A, Rosner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F and Rnuechel R: Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 80: 709-718, 2000. (Pubitemid 30340655)
7. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R and Dinney CP: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6: 4866-4873, 2000. (Pubitemid 32110431)
8. Itano N, Sawai T, Miyaishi O and Kimata K: Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res 59: 2499-2504, 1999. (Pubitemid 29242303)
9. Delpech B, Girard N, Bertrand P, Courel MN, Chauzy C and Delpech A: Hyaluronan: fundamental principles and applications in cancer. J Intern Med 242: 41-48, 1997. (Pubitemid 27323864)
10. Sherman L, Sleeman J, Herrlich P and Ponta H: Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 6: 726-733, 1994. (Pubitemid 24295307)
11. Abetamann V, Kern HF and Elsasser HP: Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin Cancer Res 2: 1607-1618, 1996. (Pubitemid 126447457)
12. Ponta H, Sleeman J, Dali P, Moll J, Sherman L and Herrlich P: CD44 isoforms in metastatic cancer. Inv Metastasis 14: 82-88, 1994.
13. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S and Tarin D: Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149: 873-882, 1996. (Pubitemid 26334171)
14. Granberg D, Wilander E, Oberg K and Skogseid B: Decreased survival in patients with CD44-negative typical bronchial carcinoid tumor. Int J Cancer 84: 484-488, 1999.
15. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, Lange LA, Wang C, Curpen GD and Savani RC: Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 82: 19-26, 1995.
16. Crainie M, Belch AR, Mant MJ and Pilarski LM: Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 93: 1684-1696, 1999. (Pubitemid 29102497)
17. Zhang S, Chang MC, Zylka D, Turley S, Harrison R and Turley EA: The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem 273: 11342-11348, 1998. (Pubitemid 28204989)
18. Bagli DJ, Joyner BD, Mahoney SR and McCulloch L: The hyaluronic acid receptor is induced by stretch injury of rat bladder in vivo and influences smooth muscle cell contraction in vitro. J Urol 162: 832-840, 1999. (Pubitemid 29436900)
19. Cheng L and Bostwick DG: World health organization and international society of urological pathology classification and two-number grading system of bladder tumors. Cancer 88: 1513-1516, 2000.
20. Li H, Liu N, Guo L, Li JW and Liu J: Frequent expression of soluble Fas and Fas ligand in Chinese stomach cancer and its preneoplastic lesions. Int J Mol Med 5: 473-476, 2000.
21. Li H, Liu J, Hofmann M, Hamou MF and de Tribolet N: Differential CD44 expression patterns in primary brain tumors and brain metastases. Br J Cancer 72: 160-163, 1995.
22. Assmann V, Marshall JF, Fieber C, Hofmann M and Hart IR: The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci 111: 1685-1694, 1998. (Pubitemid 28330555)
23. Nemec RE, Toole BP and Knudson W: The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biochem Biophys Res Commun 149: 249-257, 1987. (Pubitemid 17162971)
24. Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP and Sy MS: Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 106: 647-651, 1996. (Pubitemid 26392770)
25. Noordzij MA, van Steenbrugge GJ, Schroder FH and van der Kwast TH: Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 84: 478-483, 1999.
26. Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC and van Meir EG: Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53: 5345-5349, 1993. (Pubitemid 23342146)
27. Iczkowski KA, Shanks JH, Allsbrook WC, Lopez-Beltran A, Pantazis CG, Collins TR, Wetherington RW and Bostwick DG: Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. Histopathology 35: 150-156, 1999. (Pubitemid 29378515)
28. Li H, Guo L, Li JW, Liu N, Qi R and Liu J: Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol 17: 927-932, 2000.
29. Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, Niimi A, Ueda M and Kimata K: Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res 90: 987-992, 1999. (Pubitemid 29500439)
30. Wang C, Thor AD, Moore DH II, Zhao Y, Kerschmann R, Stem R, Watson PH and Turley EA: The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 4: 567-576, 1998. (Pubitemid 28193554)
31. Gares SL and Pilarski LM: Balancing thymocyte adhesion and motility: a functional linkage between beta1 integrins and the motility receptor RHAMM. Dev Immunol 7: 209-225, 2000.
32. Hofmann M, Assmann V, Fieber C, Sleeman JP, Moll J, Ponta H, Hart IR and Herrlich P: Problems with RHAMM: a new link between surface adhesion and oncogenesis? Cell 95: 591-592, 1998.
33. Li H, Guo L, Li J, Liu N and Liu J: Alternative splicing of RHAMM gene in Chinese gastric cancers and its in vitro regulation. Chinese J Med Genet 17: 343-347, 2000.